Prelude Therapeutics Inc — Director's Dealing 2021

Jul 23, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Prelude Therapeutics Inc (PRLD)
CIK: 0001678660
Period of Report: 2021-07-20

Reporting Person: Scherle Peggy (Chief Scientific Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-20	Employee Stock Option (Right to Buy)	$31.23	A	95000	Acquired	2031-07-19	Common Stock (95000)	Direct

Footnotes

F1: The stock option vests as to 25% of the total shares on July 20, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.